163 related articles for article (PubMed ID: 12760891)
1. Alpha interferon augments cidofovir's antiviral and antiproliferative activities.
Johnson JA; Gangemi JD
Antimicrob Agents Chemother; 2003 Jun; 47(6):2022-6. PubMed ID: 12760891
[TBL] [Abstract][Full Text] [Related]
2. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.
Abdulkarim B; Sabri S; Deutsch E; Chagraoui H; Maggiorella L; Thierry J; Eschwege F; Vainchenker W; Chouaïb S; Bourhis J
Oncogene; 2002 Apr; 21(15):2334-46. PubMed ID: 11948417
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells.
Andrei G; Snoeck R; Schols D; De Clercq E
Oncol Res; 2000; 12(9-10):397-408. PubMed ID: 11697818
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity.
Sirianni N; Wang J; Ferris RL
Oral Oncol; 2005 Apr; 41(4):423-8. PubMed ID: 15792615
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Johnson JA; Gangemi JD
Antimicrob Agents Chemother; 1999 May; 43(5):1198-205. PubMed ID: 10223936
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines.
Andrei G; Snoeck R; Piette J; Delvenne P; De Clercq E
Oncol Res; 1998; 10(10):523-31. PubMed ID: 10338155
[TBL] [Abstract][Full Text] [Related]
7. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
8. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha.
Barnard P; Payne E; McMillan NA
Virology; 2000 Nov; 277(2):411-9. PubMed ID: 11080488
[TBL] [Abstract][Full Text] [Related]
9. Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia.
Andrei G; Topalis D; De Schutter T; Snoeck R
Antiviral Res; 2015 Feb; 114():21-46. PubMed ID: 25446403
[TBL] [Abstract][Full Text] [Related]
10. Intralesional or topical cidofovir (HPMPC, VISTIDE) for the treatment of recurrent genital warts in HIV-1-infected patients.
Orlando G; Fasolo MM; Beretta R; Signori R; Adriani B; Zanchetta N; Cargnel A
AIDS; 1999 Oct; 13(14):1978-80. PubMed ID: 10513659
[No Abstract] [Full Text] [Related]
11. Cidofovir incorporation into human keratinocytes with episomal HPV 16 results in nonselective cytotoxicity.
Spanos WC; El-Deiry M; Lee JH
Ann Otol Rhinol Laryngol; 2005 Nov; 114(11):840-6. PubMed ID: 16363057
[TBL] [Abstract][Full Text] [Related]
12. IFN-tau exhibits potent suppression of human papillomavirus E6/E7 oncoprotein expression.
Johnson JA; Hochkeppel HK; Gangemi JD
J Interferon Cytokine Res; 1999 Oct; 19(10):1107-16. PubMed ID: 10547150
[TBL] [Abstract][Full Text] [Related]
13. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects.
Zabawski EJ; Cockerell CJ
J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):741-5. PubMed ID: 9810890
[TBL] [Abstract][Full Text] [Related]
14. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference.
Jiang M; Milner J
Oncogene; 2002 Sep; 21(39):6041-8. PubMed ID: 12203116
[TBL] [Abstract][Full Text] [Related]
15. Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity.
Ruesch MN; Laimins LA
J Virol; 1997 Jul; 71(7):5570-8. PubMed ID: 9188631
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein.
Jones DL; Münger K
J Virol; 1997 Apr; 71(4):2905-12. PubMed ID: 9060648
[TBL] [Abstract][Full Text] [Related]
17. Large plantar wart caused by human papillomavirus-66 and resolution by topical cidofovir therapy.
Davis MD; Gostout BS; McGovern RM; Persing DH; Schut RL; Pittelkow MR
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 2):340-3. PubMed ID: 10901717
[TBL] [Abstract][Full Text] [Related]
18. The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenografts.
Deberne M; Levy A; Mondini M; Dessen P; Vivet S; Supiramaniam A; Vozenin MC; Deutsch E
Anticancer Drugs; 2013 Jul; 24(6):599-608. PubMed ID: 23698251
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature.
Dancey DR; Chamberlain DW; Krajden M; Palefsky J; Alberti PW; Downey GP
Chest; 2000 Oct; 118(4):1210-4. PubMed ID: 11035700
[TBL] [Abstract][Full Text] [Related]
20. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection.
Snoeck R; Bossens M; Parent D; Delaere B; Degreef H; Van Ranst M; Noël JC; Wulfsohn MS; Rooney JF; Jaffe HS; De Clercq E
Clin Infect Dis; 2001 Sep; 33(5):597-602. PubMed ID: 11477525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
